Organogenesis (ORGO) Projected to Post Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is expected to be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Organogenesis to post earnings of $0.21 per share and revenue of $172.6750 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Organogenesis Stock Performance

NASDAQ:ORGO opened at $4.03 on Wednesday. Organogenesis has a fifty-two week low of $2.61 and a fifty-two week high of $7.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The company has a 50 day moving average price of $4.34 and a 200 day moving average price of $4.61. The stock has a market capitalization of $511.45 million, a P/E ratio of -33.58 and a beta of 1.46.

Insider Activity at Organogenesis

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the sale, the director directly owned 2,565,591 shares in the company, valued at approximately $13,187,137.74. This represents a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

Large investors have recently modified their holdings of the company. First Light Asset Management LLC acquired a new stake in shares of Organogenesis in the 2nd quarter valued at $24,804,000. Deutsche Bank AG grew its stake in shares of Organogenesis by 0.4% during the fourth quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock worth $17,082,000 after purchasing an additional 13,301 shares in the last quarter. Geode Capital Management LLC increased its holdings in Organogenesis by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock valued at $9,259,000 after buying an additional 62,346 shares during the last quarter. Norges Bank acquired a new stake in Organogenesis in the fourth quarter valued at $5,686,000. Finally, Bank of America Corp DE raised its stake in Organogenesis by 27.2% in the third quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock valued at $2,581,000 after buying an additional 130,875 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ORGO has been the topic of several research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $9.00 price target on shares of Organogenesis in a research report on Friday, December 26th. Finally, Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.00.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.